Study finds breast and ovarian cancer may have similar origins
While breast cancer is the most common cause of cancer death in women worldwide, ovarian cancer also is a significant source of mortality as the fifth leading cause of cancer death among women. These facts reflect the continued need for further understanding and innovation in cancer treatment.
A new study published in the International Journal of Molecular Sciences, describes a new concept of how these two cancers may evolve in a similar way and may eventually lead to more effective therapies for both.
"Though breast and ovarian cancer are distinctly clinically different, our analysis uncovered many overlaps, particularly with respect to genetic and epigenetic alterations," explained corresponding author Sibaji Sarkar, PhD, instructor of medicine at Boston University School of Medicine (BUSM). (Epigenetics is when genetically identical cells express their genes differently, causing different outcomes.)
BUSM researchers compared genetic, micro-environmental, stromal (connective tissue cells of any organ) and epigenetic changes common between breast and ovarian cancer cells, as well as the clinical relevance of these changes. They observed that selected genes including some oncogenes and tumor suppressor genes are similarly altered in these two types of cancers.
The study also presents a new model that explains how growth promoting genes could be epigenetically turned on and growth inhibiting genes could be epigenetically turned off in cancer cell formation.
"Both breast and ovarian cancers may have a similar origin. These similarities suggest that better understanding of this process will generate more effective chemotherapeutics, as well as strategies to circumvent drug resistance and cancer relapse," added Sarkar.
Most read news
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New gene transfer strategy shows promise for limb girdle and other muscular dystrophies

Analytik Jena - Pöttelsdorf, Austria
Science for the protection of consumers - BfR publishes its Annual Report for 2008
MorphoSys Achieves Clinical Milestone and Payment in Antibody Alliance

The future of personalized cancer treatment: An entirely new direction for RNAi delivery
Ebola virus disarmed by excising a single gene
A novel human stem cell-based model of ALS opens doors for rapid drug screening
Researchers identify phosphorylation process vital to cancer growth
Analytica 2014: New special exhibit for occupational health and safety
VIB-UGent scientist Jirí Friml receives Körber European Science Award 2010 for research on plant hormones and development
